Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Despite the availability of several new systemic agents for psoriasis treatment, choosing the
right therapy in certain patient populations can be challenging. There are few up-to-date …

The emergence of data from clinical trials of biologics, the approval of new biologics, and
our improved understanding of psoriasis pathogenesis have increased the therapeutic …

The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because
they have dramatic efficacy. At the same time, safety concerns about biologics have been …

Introduction Pustular psoriasis is a group of skin diseases characterized by neutrophil
infiltration in the epidermis and formation of sterile pustules. Conventional treatments, such …

An advanced understanding of the pathogenesis of psoriasis has led to the development of
multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor …

Psoriasis is a chronic immune-mediated skin and joint disease, with a plethora of
comorbidities, characterized by a certain genetic predisposition, and a complex …

In patients with rheumatic diseases undergoing immunosuppressive treatment, hepatitis B
virus reactivation (HBVr) has been long recognized as a major treatment-related adverse …

Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the
world's population. Systemic treatments, including methotrexate and cyclosporin, are …

Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …